UK Authorization for Aflibercept   - Takeaways - MDSpire

UK Authorization for Aflibercept  

MHRA clears Eylea for macular edema following retinal vein occlusion

  • March 3, 2026

  • 2 min

Share

  • 1

    The UK MHRA has authorized aflibercept 8 mg for treating visual impairment due to retinal vein occlusion.

  • 2

    This approval is based on the Phase III QUASAR trial, demonstrating non-inferior visual acuity gains compared to aflibercept 2 mg.

  • 3

    Patients receiving aflibercept 8 mg required fewer injections on average than those receiving the 2 mg formulation.

  • 4

    Over 60% of patients in the 8 mg group achieved treatment intervals of four months or longer by week 64.

  • 5

    The authorization aims to reduce injection burden while maintaining visual outcomes for patients with RVO.

Original Source(s)

UK Authorization for Aflibercept  

  • March 3, 2026

Related Content

Medical Oddities: Do Jellyfish Hold a Healing Secret?

Jellyfish, pets, watermelon, brain implants, and fennel fuel this week's surprises.

Early Fluid Resolution Predicts Faricimab Durability

Post hoc analysis suggests rapid retinal fluid resolution may help identify patients with nAMD who can maintain longer faricimab dosing intervals.

Evaluation of Laser Doppler Holography for Assessing Choroidal Blood Flow: A Comprehensive Review of Technical Features, Validation Research, and Clinical Uses